Muscarinic And Nicotinic Blockers Flashcards
The efferent (motor) division of the PNS is sub-divided into ______ Nervous System and the ______ Nervous System.
Somatic
Autonomic
The somatic nervous system innervates the ______ muscles.
The ANS supplies motor impulses to ____ muscle, _____ muscles and to the glandular epithelium.
skeletal
cardiac; smooth
The ANS is divided into ______ and ______ systems.
sympathetic and the parasympathetic
Autonomic efferent pathway uses ___ neurons arranged in ___ to integrate CNS to the peripheral organs.
Somatic efferent pathway, however, uses _____ neuron for the integration of CNS to the skeletal muscles
two; series
a single
Cholinergic Transmission: Site Differences
Skeletal Muscle
Neurotransmitter:_______
Receptor type: _______
Acetylcholine
Nicotinic
Cholinergic Transmission: Site Differences
Autonomic Effectors
Neurotransmitter: _______
Receptor type:_________
effector coupled to receptor by _______
Acetylcholine
Muscarinic
a G protein
Cholinergic Transmission: Site Differences
Autonomic Ganglia
Neurotransmitter: ______
Receptor type: _____
Acetylcholine
Nicotinic
Nicotinic Receptor Agonists
These are drugs that mimic the action of acetylcholine at __________ receptor sites.
Examples include: ???
nicotinic acetylcholine
nicotine, acetylcholine, choline, epibatidine, lobeline, varenicline and cytisine
Ganglion stimulants
These are drugs which stimulate the ___ receptors in ___________ ganglia.
nicotinic
both sympathetic and parasympathetic
Ganglion stimulants
The dominant receptors are the _________.
In addition, there are subsidiary ___________________________________ receptors
nicotinic NN
M1, M2, adrenergic, dopaminergic, aminergic and peptidergic
autonomic ganglion is a one transmitter – one cell junction system
T/F
F
autonomic ganglion is not merely a one transmitter – one cell junction, but a complex system
therapeutic application of ganglion stimulants??
There is no therapeutic application of ganglion stimulants , as no useful purpose could be served by stimulating both sympathetic and parasympathetic ganglia concurrently.
Ganglion stimulants
Nicotine is available as ________ for treating nicotine dependence and as an aid to smoking cessation.
It ameliorates the symptoms of _________ but does not completely ______
transdermal patches
nicotine withdrawal
suppress craving.
Varenicline:
As a ___________, it reduces both the __________ and ________ of cigarettes and other tobacco products. Through these mechanisms it can assist some patients to quit smoking.
partial agonist
craving for and the pleasurable effects
ANTICHOLINERGIC DRUGS
Also known as Cholinergic Antagonists, ___________
Parasympatholytics
ANTICHOLINERGIC DRUGS
If via the nicotinic receptors, they are referred to as “______,” and “________.”
Ganglion blockers
Neuromuscular blockers
Muscarinic Receptor Subtypes:
M1
Location: ____ neurones , _____
Functions: Improves learning, memory, motor functions
Gastric glands:____ release, ___ secretion
Salivary: ____eased secretion
Clinical Effects: _____ Secretion
Clinically Selective Anticholinergic Drugs:
____,_____,____,______
CNS; Stomach
histamine; acid ; incr
Hydrogen Ion
Pirenzepine, Telenzepine, Dicyclomine, trihexyphenidyl
M1 is It is primarily a _____ receptor
neuronal
M2:
Location: ____,_____
- Functions: SA node: ____polarization, (enhanced or reduced?) rate of impulse generation
- AV node: (enhanced or reduced?) conduction velocity
- Atrium: (shortening or lengthening ?) of APD, (enhanced or reduced?) contractility
- Ventricle: (enhance or reduced?) contractility
- Presynaptic terminals/Cholinergic nerve endings of peripheral and central neurones : reduced ACh release
- CNS: tremor, analgesia
Heart, CNS
hyper ; Reduced; reduced
Shortening; Reduced
Reduced
M2 receptor exert (excitatory or inhibitory?) effects, mainly by increasing ___ conductance and by (stimulating or inhibiting?) _____ channels. Thus, its activation is responsible for the vagal ____ of the heart, as well as presynaptic ______ in the CNS and periphery.
inhibitory
K+; inhibiting; calcium
inhibition
inhibition
M2:
Clinical Effects: ______
Clinically Selective Anticholinergic Drugs: _______,_________
Bradycardia
Tripitamine, Methoctramine
M3:
Effects mainly (excitatory or inhibitory?) , except on the ______ muscle, where its activity is mediated through the release of ___, to produce vaso______.
excitatory; vascular smooth; NO
dilatation
M3:
- Location : ______,_____,_______,_____
Clinical Effects
CNS - Visceral smooth muscle (contraction or relaxation?)
- Iris (pupillary (constriction or dilatation?)
Smooth muscles, endocrine glands, lungs, pancreas
Contraction
Constriction
M3
Clinical effects
-Ciliary muscle (contraction or relaxation)
- Exocrine glands (______)
- Vascular endothelium (release of ___ to produce vaso____)
Clinically Selective Anticholinergic Drugs:
Mention 4
Contraction
Secretion
NO; dilatation
Darifenacin, Solifenacin, oxybutynin, tolterodine.